CAD 0.09
(-10.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.10 CAD | 9.09% |
2022 | -0.11 CAD | 38.89% |
2021 | -0.18 CAD | 53.85% |
2020 | -0.39 CAD | -8.33% |
2019 | -0.36 CAD | 69.49% |
2018 | -1.18 CAD | -2771.05% |
2017 | -0.04 CAD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.02 CAD | -6.29% |
2024 Q1 | -0.01 CAD | 62.86% |
2023 Q4 | -0.04 CAD | -126.47% |
2023 Q2 | -0.02 CAD | 0.0% |
2023 FY | - CAD | 9.09% |
2023 Q3 | -0.02 CAD | 25.76% |
2023 Q1 | -0.02 CAD | 16.42% |
2022 Q2 | -0.02 CAD | -30.85% |
2022 Q4 | -0.03 CAD | 23.03% |
2022 FY | - CAD | 38.89% |
2022 Q1 | -0.02 CAD | 31.88% |
2022 Q3 | -0.04 CAD | -44.72% |
2021 Q1 | -0.05 CAD | 72.41% |
2021 FY | - CAD | 53.85% |
2021 Q4 | -0.03 CAD | 53.38% |
2021 Q3 | -0.06 CAD | -19.84% |
2021 Q2 | -0.05 CAD | -5.33% |
2020 Q4 | -0.17 CAD | -228.19% |
2020 Q3 | -0.05 CAD | 29.62% |
2020 Q1 | -0.07 CAD | 46.77% |
2020 Q2 | -0.07 CAD | -6.36% |
2020 FY | - CAD | -8.33% |
2019 Q1 | -0.08 CAD | -27.91% |
2019 FY | - CAD | 69.49% |
2019 Q4 | -0.13 CAD | -229.11% |
2019 Q3 | -0.04 CAD | 19.55% |
2019 Q2 | -0.05 CAD | 41.13% |
2018 Q3 | -0.18 CAD | -20.0% |
2018 FY | - CAD | -2771.05% |
2018 Q1 | -0.91 CAD | -2726.09% |
2018 Q2 | -0.15 CAD | 83.52% |
2018 Q4 | -0.07 CAD | 63.78% |
2017 FY | - CAD | 0.0% |
2017 Q4 | -0.03 CAD | 21.65% |
2017 Q3 | -0.04 CAD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Aequus Pharmaceuticals Inc. | -0.02 CAD | -346.429% |
CanadaBis Capital Inc. | 0.03 CAD | 408.642% |
Decibel Cannabis Company Inc. | -0.00 CAD | -2225.581% |
Delivra Health Brands Inc. | 0.00 CAD | 3325.806% |
Entourage Health Corp. | -0.15 CAD | 33.333% |
Lifeist Wellness Inc. | -0.58 CAD | 82.759% |
Cannara Biotech Inc. | 0.08 CAD | 228.535% |
Medicure Inc. | -0.09 CAD | -13.25% |
Rubicon Organics Inc. | -0.03 CAD | -209.598% |
BioSyent Inc. | 0.54 CAD | 118.519% |
Voyageur Pharmaceuticals Ltd. | -0.01 CAD | -834.579% |